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Objectives. Since early detection improves overall survival in lung cancer, identification of screening biomarkers for patients at risk
represents an area of intense investigation. Tumor liberated protein (TLP) has been previously described as a tumor-associated
antigen (complex) present in the sera from lung cancer patients. Here, we set out to identify the nature of TLP to develop this as a
potential biomarker for lung cancer screening.Materials andMethods. Beginning from the peptide epitope RTNKEASI previously
identified from the TLP complex, we produced a rabbit anti-RTNKEASI serum and evaluated it in the lung cancer cell line A549
by means of immunoblot and peptide completion assay (PCA). +e TLP sequence identification was conducted by mass
spectrometry. +e detected protein was, then, analyzed in patients with non-small cell lung cancer (NSCLC) and benign lung
pathologies and healthy donors, by ELISA. Results. +e anti-RTNKEASI antiserum detected and immunoprecipitated a 55 kDa
protein band in the lysate of A549 cells identified as aldehyde dehydrogenase isoform 1A1, revealing the molecular nature of at
least one component of the previously described TLP complex. Next, we screened blood samples from a non-tumor cohort of 26
patients and 45 NSCLC patients with different disease stages for the presence of ALDH1A1 and global ALDH. +is analysis
indicated that serum positivity was highly restricted to patients with NSCLC (ALDH p< 0.001; ALDH1A1 p � 0.028). In-
terestingly, the global ALDH test resulted positive in more NSCLC samples compared to the ALDH1A1 test, suggesting that other
ALDH isoformsmight add to the sensitivity of the assay. Conclusion. Our data indicate that ALDH levels are elevated in the sera of
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1. Introduction
Despite various treatment approaches such as surgery, ra-
diotherapy, and chemotherapy, lung cancer remains the
most common cancer-related cause of death in the world
with a 15% 5-year survival rate of about [1–3]. Non-small cell
lung cancer (NSCLC) represents the most frequent histology
and accounts for 80–85% of newly diagnosed cases. +e
standard of care for functionally operable early-stage and
resectable stage IIIA NSCLC is surgery which possesses a
potential for cure. Nevertheless, only 20% of NSCLC are
diagnosed at early stage and can be resectable; thus, early
detection strategies remain an unmet clinical need [4–6].
So far, numerous studies investigated mainly the po-
tential effects of chest X-rays and low-dose helical computed
tomography (CT) for imaging alongside with sputum cy-
tology on lung cancer detection. Although these studies
showed encouraging results about stage distribution in favor
of earlier stage disease, better surgical resection of the tu-
mors, and also an increased survival rate, an improvement
on overall mortality could not be determined [7–16]. Se-
rological markers such as Carcinoembryonic antigen (CEA),
neuron-specific enolase (NSE), and Cyfra 21-1 are sero-
logical markers used for the monitoring of treatment re-
sponse in lung cancer patients, but their application as
screening biomarkers is still a challenging question [17–19].
+eoretically, an ideal biomarker should be 100% sensitive
and specific, a goal that is almost never accomplished. One
strategy potentially increasing both parameters is to putting
different biomarkers together into a screening marker panel.
+is approach, along with other noninvasive methods, may
allow for further improvement of NSCLC screening [20].
In 1983, a tumor-associated antigen was isolated from
NSCLC and named tumor liberated protein (TLP) by Tarro
et al. and immunohistochemically localized in small and
large granules into the cytoplasm [4, 21–25]. Given that it
was also detected in the lumen of atypical glands and in the
bronchial secretions of some specimens, TLP could be
considered a secretory product of cancer cells. It has been
shown that when TLP is isolated and purified from a pa-
tient’s tumor and reintroduced into the body, it boosts an
immune response in the host [4]. Starting from the partial
sequence analysis of this protein, corresponding antigenic
peptides have been synthetized and used to generate antisera
in rabbits. Among the four TLP-derived peptides identified
by Tarro, anti-RTNKEASI rabbit sera reacted specifically
with NSCLC tumor extracts and sera from lung cancer
patients [26]. TLP was detected in the sera of NSCLC pa-
tients above all at the early stage of disease.
In this study, we show that TLP (or a component of this
putative complex) corresponds to aldehyde dehydrogenase
(ALDH) isoform 1A1 (ALDH1A1). ALDHs are a broad
family of intracellular enzymes that are involved in cellular
detoxification, differentiation, and drug resistance processes
by means of the conversion of exogenous and endogenous
aldehydes to carboxylic acids [4, 6, 27–30]. Numerous
studies have investigated the biological role of ALDH in
cancers including breast cancer, colon cancer, head and
neck, papillary thyroid carcinoma, and mainly lung cancer,
where they have given supportive evidence for the corre-
lation between ALDH activity and lung cancer stem cells
[4, 31–37]. Moreover, Cao et al. showed that ALDH1A1
levels were elevated in the sera of NSCLC patients. +e
combination of serum ALDH1A1 and CEA significantly
increased the screening sensitivity of single CEA test [38].
Here, we show that ALDH isoforms other than 1A1 may be
released into the blood of NSCLC patients, and thus,
screening sensitivity may be even more improved by
employing an isoform-unspecific global ALDH assay
without apparently lowering specificity. Diagnostic sensi-
tivity and specificity will, however, have to be prospectively
validated in larger cohorts of patients with early-stage
NSCLC and in healthy subjects at risk for NSCLC as well as
in other cancer patient cohorts.
2. Materials and Methods
2.1. Patient Characteristics and Materials. Blood samples
from 45 newly diagnosed NSCLC patients, 17 patients with
benign lung pathologies, and 9 healthy donors were collected
during routine diagnostic workup. +e work has been carried
out in accordance with the declaration of Helsinki. All pa-
tients consented to the use of their biological material for this
investigation as approved by the Landesärztekammer Ham-
burg (ethics committee) (project number PV4382). Patients
with lung cancer stages I-IIIA were considered as early-stage
disease, as previously published [30]. Clinical characteristics
(type of lung cancer, patient age, sex, smoking, tumor his-
tology, tumor stage, and secondary diagnosis) of this cohort
are displayed in Table 1.
2.2. Antigen Synthesis and Antibody Production. +e pro-
duction of two different rabbit polyclonal anti-RTNKEASI
immune sera and the synthesis of TLP-derived peptide
RTNKEASI [26] were both conducted at Rockland Im-
munochemicals Inc. (Gilbertsville, PA, USA) and at Bio-
Genes GmbH (Berlin, Germany). We further purified the
anti-RTNKEASI immune serum produced at Rockland by
means of chromatography against the RTNKEASI peptide.
2.3. Cell Culture. +e human cell lines MRC-5, A549, Hela,
CA46, HL60, PC3, and MCF-7 were obtained from
American Type Culture Collection (ATCC; Manassas, VA,
USA). Cell lines were cultured at 37°C in a humidified at-
mosphere of 5% CO2 in air under the following conditions:
CA46 cell line in Glutamax RPMI 1640; PC3 cell line in
Glutamax HAM’s F-12; MRC-5, HL60, MCF-7, A549, and
Hela cell lines in Glutamax Dulbecco’s Modified Eagle’s
Medium. All the media (Gibco, Life Technologies) were
supplemented with 10% fetal bovine serum (Biochrom
GmbH, Berlin, Germany) [39].
2.4. Western Blot. We prepared cell pellets and lysates from
MCF-7, CA46, HL60, PC3 MRC-5, A549, and Hela cell lines
as described previously [39, 40].
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Cell culture supernatant from A549 cells (5×106) was
treated on ice with 10% trichloroacetic acid (TCA) and then
incubated with ice-cold 90% acetone at − 20°C. Subsequently,
the sample was centrifuged and the pellet dried at 65°C for
30minutes.
+e isolated proteins were mixed in Laemmli sample
buffer (20% glycerol, 4% sodium dodecyl sulfate (SDS),
100mM Tris-HCl, 200mM dithiothreitol (DTT), and 0.01%
bromophenol blue) and boiled before loading into SDS-
PAGE gel. Finally, the proteins were blotted onto mem-
branes and blocked in nonfat dry milk 8%+PBS + 0.1%
Tween-20 before hybridization with the anti-RTNKEASI
serum diluted 1 :1000 in PBS+ 0.1% Tween-20 +BSA 5%
buffer or β-actin 1 : 20000 (Biolegend, San Diego, CA),
overnight at 4°C. After primary antibodies, the membranes
were probed with a secondary antibody (1 : 30000 in
PBS + 0.1% Tween-20 + BSA 5%), and then, proteins were
visualized by enhanced chemiluminescence (GE Healthcare,
Little Chalfont, UK).
2.5. PCA. +e anti-RTNKEASI serum (1 : 1000) was sub-
jected to preincubation with peptide RTNKEASI (500-
fold molar excess) or KDSGNEQTFLPP as a control
peptide, before hybridization with blotted A549 sample
for 2 hours, according to Rockland procedure. +e
membranes were probed with a secondary antibody, and
immunoreactive bands were detected by enhanced
chemiluminescence.
2.6. 2D Polyacrylamide Gel Electrophoresis. Protein isolation
from cell lines was performed as described previously [41].
For the first dimension isoelectric focusing, we used 7 cm
immobilized pH gradient (IPG) dry strips with a linear pH
4–7 gradient (GE Healthcare). Solubilized proteins (50 μg)
were put onto the strips, rehydrated, and incubated over
night [41]. Proteins were resolved by the PROTEAN IEF
system (Bio-Rad) (voltage gradient at 20°C with a current
limit of 50 μA) under the following conditions: 4 h at 250V,
8000V linear gradient to 15000V·h, and rapid 8000V to
75000V h, for a total of 90 kV·h [41]. After equilibration in
buffer 1 (130mM DTT, 6M urea, 20% glycerol, 0.05M Tris-
HCl, 2% SDS) and buffer 2 containing iodoacetamide in
place of DTT, the first dimension strips were positioned to
the upper part of 8% acrylamide (Applichem GmbH,
Darmstadt, Germany), for performing the second di-
mension [41]. +e separated proteins were stained by silver
or blotted onto the membrane and probed with the pre-
serum or anti-RTNKEASI serum.
2.7. Protein Identification by LC-MS/MS. +e gel spots were
treated with DTT (10mM, 56°C, 30min) and with iodoa-
cetamide (55mM, at room temperature, 20min, in the
dark). Subsequently, the proteins were digested by 13 ng/μl
trypsin (sequencing grade modified trypsin, Promega) in
50mM ammonium bicarbonate, 37°C, 16 h. Tryptic digested
peptides were extracted in 65% acetonitrile (ACN)/5%
formic acid (FA), vacuum-dried, and dissolved in 15 μL 0.1%
FA. Tryptic digested peptides were separated on an UltiMate
3000 Rapid Separation liquid chromatography (RSLC)
system (Dionex, +ermo Scientific, Bremen, Germany)
coupled online via electrospray-ionization (ESI) to an
Orbitrap Fusion Tribrid mass spectrometer (+ermo Scien-
tific, Bremen, Germany). +e samples were loaded with a flow
rate of 5μl/min on a trapping column (Acclaim PepMap









Age in years, mean± SD 42.7± 18.0 53.1± 18.3 68.5± 8.2 62.3± 8.8
Male, no. (%) 2 (22.2) 10 (58.8) 12 (48.0) 10 (50)
Smoker, no. (%) 0 11 (64.7) 20 (80.0) 15 (88.0)∗
Smoking in pack-years, mean± SD 0 28.4± 29.5 43.6± 30.6 47.3± 22.05
Type of lung cancer, no. (%)
NSCLC 25 (100.0) 20 (100.0)
Adenocarcinoma 15 (60.0) 13 (65)
Squamous cell carcinoma 8 (32.0) 2 (10)
Large cell carcinoma 2 (8.0) 1 (5)








Type of benign lung diseases, no. (%)
COPD 8 (47.1)
Cystic fibrosis 4 (23.5)
Other benign lung diseases∗∗ 5 (29.4)
NSCLC: non-small cell lung cancer; COPD: chronic obstructive pulmonary disease. ∗Smoking status of 3 patients unknown. ∗∗Other benign lung diseases
comprise precapillary pulmonary hypertension (n� 2), interstitial lung disease (n� 1), sarcoidosis (n� 1), and mucoid impaction (n� 1).
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μ-precolumn, C18, 300 μm× 5mm, 5μm, 100Ǻ, +ermo
Scientific, Bremen, Germany; nanoACQUITY-UPLC Sym-
metry C18 trap column, 180μm× 20mm, 5μm, 100Ǻ; buffer
A: 0.1% FA inHPLC-H2O; buffer B: 0.1% FA in ACN)with 2%
buffer B. +e loaded samples on the trapping column were
washed firstly for 5min with 2% buffer B (5μl/min) and
subsequently the peptides were eluted (200 nl/min) onto the
separation column. Tryptic digested peptides were separated
on a reversed-phase C18 column (Acclaim PepMap 100,
75μm× 25mm, 2μm, 100Å; +ermo Scientific, Bremen,
Germany; nanoACQUITY-UPLC column, BEH 130 C18,
Waters; 75 μm× 250mm, 1.7μm, 100Ǻ) with a flow rate
200nl/μmwith a binary buffer system of solvent A (0.1% FA in
HPLC-H2O) and solvent B (0.1% FA in ACN). +e peptides
were eluted with a gradient of 2–30% Solvent B in 30min. MS
analysis was performed in the positive ion mode and was
programmed to acquire by data-dependent mode (DDA).+e
full scans were acquired in the Orbitrap mass analyzer of
Fusion with a resolution of 120,000 FWHM atm/z 200 on the
MS level over a m/z range from 400 to 1500 (maximum in-
jection time: 50ms and automatic gain control target: 4e5).
+e fragmentation was carried out with an intensity threshold
of 1e4, and the fragmented ions were accumulated in the linear
ion trap in the rapid mode. Only precursors with charge states
between +2 and +5 and the most intense precursors were
selected for fragmentation. +e top intense ions were isolated
to a target value of 1e4 with a maximum injection time of
50–150ms. +e raw data were processed with Proteome
Discoverer, v1.4.1.14 (+ermo Scientific). Protein identifica-
tion was performed by using UniProt FASTA database.
2.8. ALDH and ALDH1A1 ELISA Assay. Serum samples
from patients with NSCLC and benign lung pathologies and
healthy donors were collected and stored at − 80°C. +e sera
were subsequently assayed according to the manual in-
structions of the global ALDH ELISA kit with a monoclonal
antibody specific for different ALDH isoforms (Bluegene,
Biotech, Shanghai, China) and the ALDH1A1 ELISA kit
with a monoclonal antibody specific for the isoform 1A1
(Cloud-Clone Corp. Houston, TX, USA).+ree independent
sera patients’ samples are analyzed. Data are expressed as
means± SD of 3 independent experiments.
2.9. Statistics. Data were presented as means± standard
deviation (SD). We used backward stepwise linear-re-
gression modelling to analyze differences in the ALDH- and
ALDH1A1 serum levels, respectively, between patients with
and without NSCLC under consideration of age, sex, and
smoking (in pack-years). Correlation coefficients were
according to the method of Pearson. All analyses were
carried out using IBM® SPSS® version 22 or GraphPadPrism™ version 5 software. A p value of <0.05 was con-
sidered statistically significant.
3. Results
3.1. Peptide RTNKEASI Mimics a 55 kDa Protein Highly
Expressed in Lung Cancer Cell Line A549. To identify the
complete protein sequence or major component of TLP, we
produced two polyclonal antibody sera (BioGenes GmbH,
Berlin, Germany; Rockland Immunochemicals, PA, USA) by
using the peptide epitope mimic RTNKEASI derived from
TLP as previously published [25]. Compared to the pre-
immune sera, both anti-RTNKEASI sera detected one dif-
ferential protein band in the NSCLC cell line A549 at 55 kDa
(Figures 1(a) and 1(b)).
Based on these results, we performed a peptide com-
petition assay (PCA) with limiting concentrations of de-
tection antiserum and an excess of blocking RTNKEASI or
control peptide. A partial extinction of the 55 kDa protein
band in the presence of the specifically blocking RTNKEASI
peptide compared to the control peptide confirmed that the
55 kDa band was specifically recognized by RTNKEASI-
directed antibodies from the antiserum (Figure 1(c)).
In order to analyze specificity of the 55 kDa protein for
lung cancer, we subjected protein lysates from a variety of
tumor cell lines and normal lung tissue to western blot
analysis with the anti-RTNKEASI serum. Our western blot
results showed very high levels of this 55 kDa protein in the
lung cancer cell line A549, whereas all other cell lines showed
either no or faint bands at 55 kDa (Figure 2(a)).
We also analyzed the supernatant from A549 cell line to
verify cell ability to secrete ALDH outside. Our western blot
showed a specific band at 55 kDa with a considerable
amount of this protein corresponding to ALDH, as con-
firmed by mass spectrometry analysis (Figure 2(b) and
Table 2).
3.2. Mass Spectrometric Identification of ALDH1A1 as Pa-
rental Antigen Mimicked by Peptide RTNKEASI. In order to
identify the 55 kDa protein by mass spectrometry (MS), we
conducted a two-dimensional (2D) gel electrophoresis of
protein extracts from A549 and MCF-7 (negative control)
followed by western blotting and detection with the anti-
RTNKEASI serum (Figure 3). We observed two neighboring
spots at the same molecular weight of 55 kDa but with
slightly different isoelectric points, 6.54 and 6.73 re-
spectively, which exhibited reactivity with the anti-
RTNKEASI serum. +ese spots were neither detected by the
preimmune serum nor by the anti-RTNKEASI serum in the
control cell lysate (Figure 3). +ese two spots were matched
to and excised from 2D protein gels followed by MS. Our
results showed that the 55 kDa protein corresponds to
ALDH isoform 1A1 which is highly expressed in different
tumors including NSCLC. +is result was also confirmed by
MS of one dimensionally (1D) separated protein extracts
from A549 cells, A549 cell culture supernatant, and
immunprecipitations with anti-RTNKEASI serum from the
A549 lysate (Table 2). Sequence alignment of ALDH1A1
with the peptide RTNKEASI revealed no linear matches,
suggesting that this peptide only structurally mimics
ALDH1A1.
3.3. Detection of ALDH1A1 and Global ALDH in Sera of
Patients with Lung Cancer and Benign Lung Pathologies.
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To explore the utility of serum ALDH1A1 as potential
biomarker for lung cancer, we tested ALDH1A1 protein
levels in sera from 25 NSCLC patients with early-stage
disease, 20 NSCLC patients with advanced stage disease, 17
patients with nonneoplastic pulmonary diseases and 9
healthy donors. +e baseline characteristics of this cohort
are shown in Table 1. We compared ALDH serum levels in
NSCLC patients with benign lung pathologies and healthy
donors groups as negative controls to set the threshold of
background and normalize the measurements, according to
previous studies [42–44]. We found ALDH1A1 serum levels
above a sensitivity threshold of 10 ng/ml (reflecting the
estimated background noise) in only three of 45 NSCLC
patients (6.7%), while all other NSCLC patients showed
ALDH1A1 serum levels comparable with the control cohorts
(Figures 4(a) and 4(b)). However, after precluding age, sex,
and smoking (in pack-years) as nonsignificant parameters
associated with the concentration of ALDH1A1 in the
backward stepwise linear-regression analysis, overall,
ALDH1A1 serum levels differed significantly between the
lung cancer and the no-lung cancer patient groups.+e mean
difference in the ALDH1A1 concentration between no lung
cancer and lung cancer is 2.10 ng/ml, 95% CI: 0.23 ng/ml to






















































Figure 1: Western blot analysis of the polyclonal anti-RTNKEASI serum in A549 cell line. SDS gel was loaded with protein extract from
non-small cell lung cancer A549 cell line followed by electrophoresis and immunoblotting. +e blots were incubated with the preimmune
serum and the polyclonal anti-RTNKEASI serum produced in rabbits from Rockland (a) or BioGenes (b). +e 55 kDa target of anti-
RTNKEASI appears only in sera of animals after immunization, and it is absent in the presera from the same rabbit. +ese results were
confirmed with both Rockland and BioGenes antibodies. A PCA was performed by incubating the corresponding blots with the polyclonal
anti-RTNKEASI serum from Rockland, pretreated with or without the peptide RTNKEASI (c) and also β-actin, as endogenous control. +e
intensity of the band approximately at 55 kDa detected by the secondary anti-rabbit horseradish peroxidase-conjugated was reduced after
the preincubation of the antibody with the peptide RTNKEASI.
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Since the MS analysis had also revealed matches with
other ALDH isoforms (such as ALDH3A1), we hypothesized
that these might add to the sensitivity of the assay. To this end,
we performed further ELISA testings using a global ALDH
assay without isoform specificity (Figures 4(c) and 4(d)).
Remarkably, 33 out of 45 serum samples (73.3%) showed
positivity for global serum ALDH (>10 ng/ml). Only one
patient from the cohort of patients with benign lung diseases
showed ALDH serum positivity above this threshold, and all
healthy donors were serum ALDH-negative. Interestingly, of
25 patients with early-stage NSCLC, 15 patients (60%)
showed elevated ALDH levels. Overall, serum ALDH levels
were significantly elevated in the cohort of patients with
NSCLC compared to patients without lung cancer. +e mean
difference in the ALDH concentration between no lung
cancer and lung cancer is 13.90 ng/ml, 95% CI: 8.45 ng/ml to
19.35 ng/ml; p< 0.001. All the statistical analysis values are
reported in Supplementary Materials (Table 1S and 2S).
According to the method of Pearson, neither ALDH1A1
nor ALDH concentration correlated significantly with the
UICC stage (p � 0.113 and p � 0.359, respectively).
4. Discussion
Worldwide, NSCL patients have the highest mortality be-
tween patients with solid tumors, and their prognosis is
tightly stage-correlated. Nevertheless, conventional methods
for the diagnosis of NSCLC have high costs and produce
potentially false-positive outcomes. +us, the discovery of
highly sensitive, specific, noninvasive, and cost-effective
lung cancer biomarkers to use in association with con-
ventional approaches may increase the sensitivity of NSCLC
screening [4, 6, 45–47].
In this study, we show that the previously described TLP
corresponds to ALDH1A1 and potentially other ALDH iso-
forms, which are highly expressed in NSCLC tissues
[28, 33, 35–38, 46–49]. Since the peptide RTNKEASI did not
linearly match ALDH isoform amino acid sequences, we
concluded that it may structurallymimic these ALDH isoforms.
In our blood-based ELISA assays, we show that ALDH
and, in accordance with Cao et al. [38], ALDH1A1 protein
levels are statistically higher in patients with NSCLC























































Figure 2: Western blot analysis for the polyclonal anti-RTNKEASI serum in cancer cell lines and cellular supernatant. (a) Protein extracts
from non-small cell lung cancer A549, normal lung tissue MRC-5, Burkitt lymphoma CA46, leukemia HL60, breast cancer MCF-7, cervical
carcinoma Hela, and prostate cancer PC-3 cell lines were loaded into SDS gel and subjected to electrophoresis and immunoblotting with the
polyclonal anti-RTNKEASI serum from Rockland. High 55 kDa protein levels were identified in A549 cells and a lower amount in Hela, PC-
3, CA46 andHL-60 cell lines whereas no protein levels were observed inMCF-7 cell line from breast cancer and inMRC-5 from normal lung
tissue. An anti-ß-actin antibody was used for a loading control. (b) Protein extracts from cellular supernatant of non-small cell lung cancer
A549 and cell lysate from A549 and MRC-5 cells were loaded into SDS gel and subjected to electrophoresis and immunoblotting with the
polyclonal anti-RTNKEASI serum from Rockland. A specific band at 55 kDa was detected in the cellular supernatant sample with respect to
cell lysate from A549; MRC-5 was used as negative control.
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percentage of NSCLC patients (6.7%) display high
ALDH1A1 serum levels, whereas sensitivity of the global
ALDH test seems encouraging (73.3%). +is suggested that
other ALDH isoforms are also released in the sera of NSCLC
patients potentially adding to the sensitivity of this global
assay. +is finding is in accordance with previous studies
showing that several ALDH isoforms are involved in NSCLC
[38]. ALDH3A1 is highly expressed in two types of NSCLC,
adenocarcinoma and squamous cell carcinoma [48, 49].
ALDH3B1 expression was also found to be upregulated in a
high percentage of human tumors, particularly in lung
cancer [50]. Given the limited sample sizes of our cohorts,
predictions on sensitivity and specificity of this marker are
unreliable. However, it seems that the global ALDH test may
Table 2: Mass spectrometric identification of aldehyde dehydrogenase as 55 kDa target of the anti-RTNKEASI serum.
Gene symbol Protein description Unique peptides Score MW (kDa)
55 kDa band from A549 cell lysate excised from 1D gel
ALDH1A1 Retinal dehydrogenase 26 687 55.4
ALDH3A1 Aldehyde dehydrogenase, dimeric NADP-preferring 15 407 50.8
UGDH UDP-glucose 6-dehydrogenase 3 140 55.7
GSR Glutathione reductase mitochondrial 4 134 56.8
PDIA3 Protein disulfide-isomerase A3 3 93 57.1
ALDH2 Aldehyde dehydrogenase, mitochondrial 3 83 56.9
55 kDa band from A549 supernatant excised from 1D gel
ALDH1A1 Retinal dehydrogenase 1 29 742 55.5
G6PD Glucose-6-phosphate 1-dehydrogenase 26 599 59.7
ALDH3A1 Aldehyde dehydrogenase, dimeric NADP-preferring 10 303 50.8
55 kDa band from A549 immunoprecipitation excised from 1D gel
ALDH1A1 Retinal dehydrogenase 1 28 351 55.5
G6PD Glucose-6-phosphate 1-dehydrogenase 12 223 59.7
ALDH3A1 Aldehyde dehydrogenase, dimeric NADP-preferring 3 70 50.8
55 kDa spot 1 from A549 lysate excised from 2D gel
ALDH3A1 Aldehyde dehydrogenase, dimeric NADP-preferring 20 515 50.4
CCT2 T-complex protein 1 subunit beta 18 100.8 57.5
ALDH1A1 Retinal dehydrogenase 1 12 57.4 54.8
ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 11 52 57.2
55 kDa spot 2 from A549 lysate excised from 2D gel
ALDH3A1 Aldehyde dehydrogenase, dimeric NADP-preferring 19 494.8 50.4
ALDH1A1 Retinal dehydrogenase 1 19 120.45 54.8
MW: molecular weight.



































MCF-7 + anti-RTNKEASI serumMCF-7 + pre-immune serum
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Figure 3: 2D gel electrophoresis and western blot analysis with cell lysates from A549 and MCF-7 cell lines using the polyclonal anti-
RTNKEASI serum and preimmune serum. Protein extract from A549 and MCF-7 cells were loaded in 2D gel followed by electrophoresis
and transferred to PVDF for immunoblotting with the polyclonal anti-RTNKEASI serum or preserum. A rectangle marks the location of the
ALDHs detected with the polyclonal anti-RTNKEASI serum in A549 cells; the reactive spots indicated with arrows were absent in MCF-
7 cells and in the blot incubated with the preserum. +ese protein spots at 55 kDa, excited and subjected to MS analysis, correspond to
ALDH1A1.
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not significantly decrease specificity as compared to the
ALDH1A1-specific test.
ALDH1A1 and ALDH3A1 expression levels in normal
pneumocytes are significantly higher in tobacco smokers
versus nonsmokers [48]. Although we did not identify any
significant association between ALDH levels and smoking
status across the cohorts, the higher expression levels in
smokers may explain the trend towards higher ALDH levels
in patients with benign lung pathologies (including a high
percentage of patients with chronic obstructive pulmonary
disease) compared to our nonsmoking healthy donors.
Our very small percentage of ALDH1A1-positive
NSCLC patients (6.7%) clearly contrasts with previously
published work by Cao et al. [38] who detected a much
higher percentage of ALDH1A1-positive NSCLC patients
(55%). +is may be due to differences in ALDH1A1 kits,
which presumably contain monoclonal antibodies with
different specificity for ALDH1A1 but may also be explained
in part by differences in the patient cohorts or different cut-
off levels. Moreover, our results showed that some patients
positive with ALDH1A1 were not with global ALDH,
probably due to a potential degradation of these samples as
global ALDH was performed later in time.
In conclusion, elevated ALDH serum levels can be de-
tected in the vast majority of patients with early- and ad-
vanced-stage disease. +erefore, serum ALDH should be
evaluated as part of a marker panel for noninvasive detection
of early NSCLC in a larger cohort of patients at risk.
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Figure 4: ELISA assay for sera (a, b) ALDH1A1 and (c, d) ALDHs. Sera samples from patients with NSCLC and benign lung pathologies and
healthy donors were collected and subjected to an enzyme-linked immunosorbent assay with amonoclonal antibody recognizing specifically
the isoform ALDH1A1 and all ALDH isoforms, respectively. (a) and (c) show individual data points, expressed as means± SD of 3
independent experiments, while (b) and (d) show summary statistics. Boxes and whiskers represent median and (interquartile) range. A
backward stepwise linear-regression modelling was used to analyze differences in ALDH1A1 and ALDH concentrations between patients
with and without lung cancer after precluding age, sex, and smoking (in pack-years) as nonsignificant independent covariables.
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[44] A. Klupczynska, P. Dereziński, J. Matysiak, W. Dyszkiewicz,
M. Kasprzyk, and Z. J. Kokot, “Determination of 16 serum
angiogenic factors in stage I non-small cell lung cancer using a
bead-based multiplex immunoassay,” Biomedicine & Phar-
macotherapy, vol. 88, pp. 1031–1037, 2017.
[45] V. Brower, “Biomarker studies abound for early detection of
lung cancer,” JNCI Journal of the National Cancer Institute,
vol. 101, no. 1, pp. 11–13, 2009.
[46] Y. Zhou, Y. Wang, X. Ju et al., “Clinicopathological signifi-
cance of ALDH1A1 in lung, colorectal, and breast cancers: a
meta-analysis,” Biomarkers in Medicine, vol. 9, no. 8,
pp. 777–790, 2015.
[47] P. Marcato, C. A. Dean, R.-Z. Liu et al., “Aldehyde de-
hydrogenase 1A3 influences breast cancer progression via
differential retinoic acid signaling,” Molecular Oncology,
vol. 9, no. 1, pp. 17–31, 2015.
[48] M. Patel, L. Lu, D. S. Zander, L. Sreerama, D. Coco, and
J. S. Moreb, “ALDH1A1 and ALDH3A1 expression in lung
cancers: correlation with histologic type and potential pre-
cursors,” Lung Cancer, vol. 59, no. 3, pp. 340–349, 2008.
[49] J. S. Moreb, H. V. Baker, L.-J. Chang et al., “ALDH isozymes
downregulation affects cell growth, cell motility and gene
expression in lung cancer cells,” Molecular Cancer, vol. 7,
no. 1, p. 87, 2008.
[50] S. A. Marchitti, D. J. Orlicky, C. Brocker, and V. Vasiliou,
“Aldehyde dehydrogenase 3B1 (ALDH3B1): immunohisto-
chemical tissue distribution and cellular-specific localization
in normal and cancerous human tissues,” Journal of Histo-
chemistry and Cytochemistry, vol. 58, no. 9, pp. 765–783, 2010.
Journal of Oncology 11
